Human TGFalpha-derived peptide TGFalphaL3 fused with superantigen for immunotherapy of EGFR-expressing tumours
<p>Abstract</p> <p>Background</p> <p>Monoclonal antibodies have been employed as targeting molecules of superantigen for the preclinical treatment of a variety of tumours. However, other targeting molecules, such as tumour-related ligands or peptides, are less exploited...
Main Authors: | Cao Cheng, Liu Chuanxuan, Yue Junjie, Zhang Xiaojuan, Xu Quanbin, Zhong Hui, Ma Qingjun |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-12-01
|
Series: | BMC Biotechnology |
Online Access: | http://www.biomedcentral.com/1472-6750/10/91 |
Similar Items
-
Zytogenetische Untersuchungen an Pankreaskarzinom-Zelllinien transgener TGFalpha/p53+/-Mäuse
by: Böhm, Christian
Published: (2005) -
Studies on vascular response to full superantigens and superantigen derived peptides: Possible production of novel superantigen variants with less vasodilation effect for tolerable cancer immunotherapy
by: Sara S. Bashraheel, et al.
Published: (2019-07-01) -
Antigen and superantigen presentation as defined by the MHCII-accessory proteins and associated-peptides
by: Fortin, Jean-Simon
Published: (2015) -
Superantigens: procession of frets
by: Bilal Aslam, et al.
Published: (2017-05-01) -
Clarifying the mechanism of superantigen toxicity.
by: John D Fraser
Published: (2011-09-01)